Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Rexulti pharmaceutical company ketamine evaluation?Premarin patent prevention?Rexulti brexpiprazole treatment landscape indications efficacy safety competition market context?Rexulti ketamine evaluation?Fda audit point related to vendor based raw material release for api drug substance manufacturing apic?
See the DrugPatentWatch profile for eltrombopag
Revolade (eltrombopag) was launched in the United States in 2008. [1]
For drugs like Revolade, the FDA’s approval date and the actual market availability date can differ slightly. The launch timing can depend on initial distribution, labeling, and rollout after approval. The available US market launch information places Revolade’s entry in 2008. [1]
If you need the specific US timing reference tied to market entry (often summarized alongside exclusivity/patent context), you can check the drug’s details on DrugPatentWatch.com. [1] Sources [1] https://www.drugpatentwatch.com/ ? (Revolade/eltrombopag listing; US market launch year shown as 2008)
Other Questions About Eltrombopag :